SonoThera raises $125M Series B to advance nonviral genetic medicine platform
What's the deal? SonoThera, a South San Francisco biotech, has closed an oversubscribed $125M Series B to advance its genetic medicine platform into clinical trials. The round was led by Vida VenturesDealroom has a profile for this one. Try Dealroom →, with participation from ARK InvestDealroom has a profile for this one. Try Dealroom →, Leaps by BayerDealroom has a profile for this one. Try Dealroom →, Otsuka PharmaceuticalDealroom has a profile for this one. Try Dealroom →, ARCH Venture Partners, RA Capital, Johnson & Johnson Innovation – JJDC, and others.
The company plans to use the proceeds to move its lead programmes — targeting Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) — into the clinic, expand its pipeline, and scale its delivery technology.
Why now? Traditional viral-based gene therapies face stubborn limitations: payload size constraints, immune responses, safety concerns, and difficulty with repeat dosing. Investor appetite is growing for alternative delivery approaches that could sidestep these problems.
SonoThera's platform combines two proprietary technologies: RIPPLE, an ultrasound-mediated delivery system, and PORE, a payload engineering platform supporting DNA therapeutics, RNA therapeutics, gene editing, and gene silencing. Rather than relying on viral vectors, it uses FDA-cleared diagnostic ultrasound systems and commercially available contrast agents to deliver genetic payloads in outpatient procedures lasting roughly an hour.
"Despite remarkable scientific progress, many diseases remain beyond the reach of today's genetic medicines," said Kenneth GreenbergDealroom has a profile for this one. Try Dealroom →, co-founder and chief executive officer. "We founded SonoThera to take a fundamentally different approach."
What could go wrong? The platform is still preclinical. Moving from promising animal data to safe, effective human treatments is where most gene therapy hopefuls stumble. The company must demonstrate that ultrasound-mediated delivery works reliably and safely across tissues in patients — not just in lab settings.
Competition is fierce. Multiple biotechs are developing nonviral delivery systems, and any clinical setback could erode the confidence that attracted this broad investor syndicate.
The signal: SonoThera's $125M Series B — oversubscribed and backed by 16 investors spanning specialist biotech funds like Vida Ventures and ARCH Venture Partners, pharma corporate arms such as Leaps by Bayer and Johnson & Johnson Innovation, and crossover names like ARK Invest — underscores widening conviction that nonviral delivery is where the next wave of genetic medicine value will be created. Dealroom classifies SonoThera as a "breakout stage" company, and the breadth of this syndicate suggests the sector sees ultrasound-mediated delivery not as a niche bet but as a potential platform shift away from the viral vectors that have defined — and constrained — gene therapy's first generation.
Read more: citybiz
